Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Type 1 Diabetes Mellitus Condition: Initial dose |
Dose: Subcutaneous – One third of the total daily insulin requirements Frequency: once daily Note: Short-acting, premeal insulin should be used to satisfy the remaining two thirds of the daily insulin requirements; insulin glargine should be used in combination with a short-acting or rapid-acting insulin; dosage should be individualized in accordance with the needs of the patient and adjusted according to blood glucose measurement; administered at the same time every day; rotate injection sites within the same region (abdomen, thigh, or deltoid) |
|
Indication: Type 2 Diabetes Mellitus Condition: Initial dose (not currently treated with insulin) |
Dose: Subcutaneous – 10 units (or 0.2 units/kg) Frequency: once daily Note: Dosage should be individualized in accordance with the needs of the patient and adjusted according to blood glucose measurement; administered at any time during the day but at the same time every day; rotate injection sites within the same region (abdomen, thigh, or deltoid) |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Type 1 Diabetes Mellitus Age: less than 6 years |
Dose: Subcutaneous Injection – Not established Note: Safety and efficacy not established |
|
Indication: Type 1 Diabetes Mellitus Age: greater than 6 years |
Dose: Subcutaneous Injection – Approximately one third of the total daily insulin requirements Note: rapid-acting or short-acting, premeal insulin should be used to satisfy the remaining two thirds of the daily insulin requirements; usual daily maintenance range in adolescents is less than 1.2 units/kg/day during growth spurts |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: dosage form not specified - dose not specified Note: Dose adjustments may be needed. |
Administration
- Inject subcutaneously only
- Do not give intravenously
Side Effect
- Hypoglycaemia
- lipodystrophy
- pruritus
- rash
- weight gain
- sodium retention and oedema
- Injection site reactions eg pain
- itching
- hives
- swelling and inflammation
- Influenza-like symptoms
- Pallor
- Palpitation
- Tachycardia
- Mental confusion
- Weakness
- Blurred vision
- Itching
- Hunger
- Nausea
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Oral antidiabetic agents, ACE Inhibitors (Captopril, Enalapril, Lisinopril, Ramipril, Benazepril, Fosinopril, Quinapril, Perindopril), disopyramide, fibrates, fluoxetine, MAOIs (Phenelzine, Tranylcypromine, Selegiline, Moclobemide), propoxyphene, salicylates, somatostatin analog (e.g. octreotide), Sulfonamide Antibiotics (Sulfamethoxazole, Sulfisoxazole, Sulfadiazine)
|
Effects may be increased
|
|
Corticosteroids (Prednisone, Prednisolone, Methylprednisolone, Dexamethasone, Hydrocortisone), niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium
|
Effects may be decreased
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypoglycemia
|
Severe low blood sugar risk
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 2° C to 8° C in a refrigerator. Do not freeze. In case of insulin for recent use need not to be refrigerated, try to keep it in a cool place and keep away from heat and light. The insulin in use can be kept under the room temperature for a month.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.